<h4>Purpose</h4>This study was performed to confirm the superiority in overall survival (OS) of EGFR tyrosine kinase inhibitor (TKI gefitinib or osimertinib) monotherapy versus EGFR TKI with intercalation of cisplatin plus pemetrexed as the first-line treatment for patients with advanced non-squamous non-small cell lung cancer (NSqNSCLC) harboring EGFR mutation.<h4>Patients and methods</h4>This was an open-label, multicenter, randomized phase III study. The gene discussed is EGFR; the disease is non-small cell squamous lung carcinoma.